August 2013: Nimotuzumab in MOGA Australia
Medical Oncology Group of Australia
Similar Posts
Update on Laryngeal Cancer
ByInnokeysSpeakers: 1. dr. Denny Satria Utama, Sp.T.H.T.L(K)., M.Si Med., FICS from Charitas Hospital Indonesia 2. Dr. dr. Fauziah Fardizza, Sp.T.H.T.K.L(K), FICS from…
Patent Granted for “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in Russia
ByInnokeysNew patent is granted with the title of “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR”…
Webinar – Nimotuzumab for Head and Neck Cancer Indication: A randomized phase 3 trial of Nimotuzumab in locally advanced head and neck cancer
ByInnokeysSpeaker: Prof. Dr. Kumar Prabhash, Medical Oncologist in Tata Memorial Hospital India The webinar was attended by more than 50…
May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
ByInnokeysKowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….
Webinar – Current Treatment of Locally Advanced Head and Neck Cancer and The Result of Randomized Phase III Study of Nimotuzumab in Locally Advanced Head and Neck Cancer
ByInnokeysSpeakers: 1. Prof. Iyer Narayanan Gopalakrishna, Head and neck surgeon in National Cancer Centre and Singapore General Hospital 2. Prof. Dr. Kumar…